Through many signaling pathways, depending largely on tumor type, TAMs up- and downregulate PD-1/PD-L1 expression, which, in turn, takes its toll on the efficacy of PD-1/PD-L1 inhibitors [105]. The gene discussed is PDCD1; the disease is neoplasm.